

GSK extends Genpact's finance contract by 5 years

17 January 2013 | News | By BioSpectrum Bureau



Singapore: Genpact, a global leader in business process management and technology services, has been awarded a five-year contract extension by global pharmaceutical leader GlaxoSmithKline (GSK) for finance and accounting (F&A) services.

According to the agreement, Genpact will continue to deliver global services such as accounts payable, record-to-report, and order-to-cash across several global regions, supporting GSK's drive to standardize core business processes and services.

Mr Paul Fry, senior vice president, finance services, core business services, GSK, said, "Our continued partnership with Genpact is a key element in our drive to deliver simpler, more efficient and standardized business processes for GSK."

Mr BK Kalra, senior vice president and business leader, life sciences, Genpact, said that, "Over the last six years, the partnership between Genpact and GSK has been able to address GSK's growing global business and the unique challenges within the pharmaceutical market while improving the outcomes of these end-to-end processes, especially through our Lean and Six Sigma framework. We are thrilled to expand our valued relationship with GSK and ensure continuous process effectiveness so that their path to future growth is smooth."

Genpact provides business process management and technology services to eight-of-the-top 10 global pharmaceutical companies. Genpact helps them to make their end-to-end F&A processes more effective, address regulatory changes, make use of customer and market data through its analytics services, and improve pharma companies' customer service operations through intelligent technology solutions.